A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions
NACompletedINTERVENTIONAL
Enrollment
30
Participants
Timeline
Start Date
February 29, 2004
Primary Completion Date
February 29, 2004
Study Completion Date
February 29, 2004
Conditions
Parkinson's DiseaseRestless Leg Syndrome
Interventions
DRUG
Ropinirole Hydrochloride
Restless Leg Syndrome
All Listed Sponsors
lead
Roxane Laboratories
INDUSTRY
NCT00673088 - A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions | Biotech Hunter | Biotech Hunter